This article was originally published in Pharmaceutical Approvals Monthly
Pooled results of two pivotal studies show improved efficacy for patients with tumor-induced hypercalcemia treated with zoledronic acid versus Novartis' Aredia (pamidronate), according to data presented at May's American Society of Clinical Oncology meeting. Complete response was shown in 69.7% of Aredia patients vs. 88.4% of Zometa 4 mg patients (p=0.002) and 86.7% of Zometa 8 mg patients (p=0.015) by day 10. CR was defined as corrected serum calcium levels of £ 10.8 mg/dL (2.7 mmol/L). Zometa also showed superiority in median time to relapse and median duration of complete response. Zometa's NDA is receiving a priority review with a user fee goal in late Jun
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.